TSE:NVLN - Novelion Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseC$13.30Today's RangeC$13.30 - C$13.3052-Week RangeC$10.68 - C$16.35VolumeN/AAverage Volume3,220 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. Receive NVLN News and Ratings via Email Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry N/A Sub-IndustryN/A SectorN/A Current SymbolTSE:NVLN Previous SymbolTSE:QLT CUSIPN/A Webwww.novelion.com Phone+1-604-7077000Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapC$0.00 OptionableOptionable Novelion Therapeutics (TSE:NVLN) Frequently Asked Questions What is Novelion Therapeutics' stock symbol? Novelion Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "NVLN." Has Novelion Therapeutics been receiving favorable news coverage? News coverage about NVLN stock has trended negative on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novelion Therapeutics earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the near future. How do I buy shares of Novelion Therapeutics? Shares of NVLN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Novelion Therapeutics' official website? The official website for Novelion Therapeutics is http://www.novelion.com/. How can I contact Novelion Therapeutics? Novelion Therapeutics' mailing address is 1800-510 Georgia St W, VANCOUVER, BC V6B 0M3, Canada. The company can be reached via phone at +1-604-7077000. MarketBeat Community Rating for Novelion Therapeutics (TSE NVLN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 74 (Vote Outperform)Underperform Votes: 56 (Vote Underperform)Total Votes: 130MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: How accurate is the Rule of 72?